Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13738MR)

This product GTTS-WQ13738MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13738MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9294MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ1941MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ4629MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ11685MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ856MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ11913MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ467MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW